Literature DB >> 30216689

Exercise testing and spirometry as predictors of mortality in congenital heart disease: Contrasting Fontan physiology with repaired tetralogy of Fallot.

Keri M Shafer1,2, Alexander R Opotowsky1,2, Jonathan Rhodes1.   

Abstract

OBJECTIVE: Risk prediction using cardiopulmonary exercise testing (CPET) in complex congenital heart disease tends to either focus on single diagnoses or complete cohorts. We aimed to evaluate patients with two distinct anatomies cared for at a single institution over the same time period to determine CPET variables associated with mortality.
DESIGN: All Fontan and tetralogy of Fallot (TOF) subjects with CPET between November 1, 2002 and December 31, 2014 and subsequently died were identified (cases). Cases were matched 1:3 to controls with similar age, underlying anatomy and timing of exercise test.
RESULTS: Of the 42 cases, 27 had a Fontan circulation and 15 with TOF. All Fontan patients had a low peak VO2 but there was no significant difference between cases and controls (52.5 ± 14.7 v. 57.4% ± 13.5% predicted, P = .11). Spirometry values were significantly lower in Fontan cases than controls (eg, FVC 67.4 ± 19.1 v 77.6% ± 14.9% predicted, P = .007). Spirometry values were also lower in TOF cases than controls (% predicted FVC 62.8 ± 16.7 v 75 ± 14, P = .006). In contrast to the Fontan analysis, both %peak predicted VO2 and VE/VCO2 slope were worse in TOF cases than controls (50.1 ± 13.5 v. 68.5% ± 15.0% predicted VO2 , P = .0004; 33.9 ± 12.9 v 26.6 ± 4.4, P = .002). Multivariable analysis also identified different predictors of mortality among the anatomic subgroups. Spirometric data (FVC) correlated most strongly with mortality in Fontan patients while the VE/VCO2 slope was most associated with outcome in TOF patients.
CONCLUSIONS: Variables most predictive of mortality in Fontan and TOF patients diverge but spirometry was abnormal and associated with mortality in both groups. When compared with age-matched controls, reduced FEV1 and FVC correlated most strongly with mortality in Fontan patients while VE/VCO2 slope correlated with mortality for TOF patients. These findings further support the importance of lung health in patients with complex congenital heart disease.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Fontan procedure; exercise testing; spirometry; tetralogy of Fallot

Mesh:

Year:  2018        PMID: 30216689     DOI: 10.1111/chd.12661

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  4 in total

1.  Does Restrictive Lung Function Affect the Exercise Capacity in Patients with Repaired Tetralogy of Fallot?

Authors:  Jyothsna Akam-Venkata; Chenni Sriram; Michelle French; Roxann Smith; Sanjeev Aggarwal
Journal:  Pediatr Cardiol       Date:  2019-09-17       Impact factor: 1.655

2.  Modified Ventricular Global Function Index Correlates With Exercise Capacity in Repaired Tetralogy of Fallot.

Authors:  Hieu T Ta; Paul J Critser; Tarek Alsaied; Joshua Germann; Adam W Powell; Andrew N Redington; Justin T Tretter
Journal:  J Am Heart Assoc       Date:  2020-07-07       Impact factor: 5.501

3.  Peak Oxygen Uptake on Cardiopulmonary Exercise Test Is a Predictor for Severe Arrhythmic Events during Three-Year Follow-Up in Patients with Complex Congenital Heart Disease.

Authors:  Felix von Sanden; Svetlana Ptushkina; Julia Hock; Celina Fritz; Jürgen Hörer; Gabriele Hessling; Peter Ewert; Alfred Hager; Cordula M Wolf
Journal:  J Cardiovasc Dev Dis       Date:  2022-07-04

4.  Cardiopulmonary Exercise Testing in Repaired Tetralogy of Fallot: Multiparametric Overview and Correlation with Cardiac Magnetic Resonance and Physical Activity Level.

Authors:  Benedetta Leonardi; Federica Gentili; Marco Alfonso Perrone; Fabrizio Sollazzo; Lucia Cocomello; Stefani Silva Kikina; Rachel M Wald; Vincenzo Palmieri; Aurelio Secinaro; Maria Giulia Gagliardi; Attilio Parisi; Attilio Turchetta; Lorenzo Galletti; Massimiliano Bianco; Fabrizio Drago
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.